Phase 2 N=20 Safety and Efficacy Study of WRSS1, a Shigella Sonnei Vaccine Candidate
Dysentery · Shigella · Diarrhea
Primary: Number of Participants With Adverse Events — 9; 5; 8; 10 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=33 Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-8655 in Participants With Type 2 Diabetes (MK-8655-002)
Type 2 Diabetes
Primary: Number of Participants With One or More Adverse Events — 11; 7 Participants
Phase 2 N=29 Pilot Biomarker Trial to Evaluate the Efficacy of Itraconazole in Patients w/ Basal Cell Carcinomas
Basal Cell Carcinoma (BCC) · Skin Cancer
Primary: Ki67 Tumor Proliferation Biomarker — 18; 0; -19; 13 Mean percent change — p=0.04
Phase 3 N=97 A Study of Subcutaneous Tocilizumab as Monotherapy and/or in Combination With Non-Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) in Participants With Rheumatoid Arthritis
Rheumatoid Arthritis
Primary: Percentage of Participants Who Achieved Disease Activity Score Based on 28 Joint Count and Erythrocyte Sedimentation Rate (DAS28-ESR) Remission at Week 24 — 40…
N/A N=364 Effectiveness of Epidural Anesthesia for Thoracic and Abdominal Surgery
Analgesia Disorder · Anesthetic Complication Epidural · Adverse Reaction to Epidural Anesthesia
Primary: Number of Patients Reporting Postoperative Verbal Rating Scale Pain at Rest More Than 7 — 89 Participants
Phase 2 N=34 Interferon and GM-CSF Compared With Imatinib Mesylate and Vaccine Therapy in Patients With Chronic Phase CML on a TKI
Leukemia
Primary: Progression-free Survival — 2; 0 Participants
N/A N=15 Rt-fMRI NF Intervention Study in ASD
Autism Spectrum Disorder
Primary: FEEST - Facial Expression of Emotion: Stimuli and Tests — 100.27; 100.79 units on a scale
N/A N=12 Study of Tarceva and Targretin in Stage I-II Lung Cancer
Carcinoma, Non-small-cell Lung
Primary: Number of Participants With Change in Expression Level of EGFR. — 3; 7 Participants
Phase 4 N=818 Lot-to-lot Consistency Trial of Japanese Encephalitis Live Attenuated SA 14-14-2 Vaccine
Japanese Encephalitis
Primary: Number/Percentage of Subjects With Demonstrated Seroprotection — 126; 160; 154; 164 Participants — p=<0.05
Phase 1 N=12 A Multiple-Dose Study to Evaluate MK-1075 in Hepatitis C Virus (HCV) Infected Participants (MK-1075-004)
Hepatitis C Virus Infection
Primary: Number of Participants Who Experienced an Adverse Event (AE) — 3; 2; 3; 2 Participants
Phase 3 N=60 Efficacy of TAP Block in Cesarean Section Patients
Pain Control
Primary: Effect of Transversus Abdominis Plane (TAP) Block Using Either 0.5% or 0.25% Bupivacaine on Analgesia for Cesarean Section Patients When Compared to Placebo. — 9.45…
N/A N=100 McGRATH MAC Video Laryngoscope
Intubation; Difficult
Primary: Number of Participants Successfully Intubated on First Attempt With Use of Either a Direct or Indirect Laryngoscopic View — 72; 16 Participants
Phase 2 N=60 Phase 2a ID93 + GLA-SE Vaccine Trial in TB Patients After Treatment Completion
Pulmonary Tuberculosis
Primary: Number of Adverse Events — 5; 4; 10; 8 participants
Phase 3 N=5,177 Prevention of Serious Adverse Events Following Angiography
Acute Renal Failure · Kidney Disease · Coronary Artery Disease
Primary: Number of Participants With Serious, Adverse, Patient-Centered Events, Including Death, Need for Acute Dialysis, or Persistent Decline in Kidney Function, Comparing…
N/A N=3,906 Testing Different Messaging Approaches to Increase Activation of a HealthyFood Benefit in Adults With Diabetes
Diabetes · Diet · Incentives
Primary: Enrollment in 10% Level of Benefit — 7; 57; 76; 48 Participants — p=<0.0001